All News

drug%20interactions.jpg

Increased Polypharmacy in SLE Patients

Jack Cush, MD

A cross-sectional study of US adults with systemic lupus erythematosus (SLE) shows significantly increased prevalence of polypharmacy, related to age, disease outcomes and often, non-SLE common medications.

Read Article
T2T.RA2_.jpg

Integrating D2T into T2T Practices in RA

EurekAlert!

Researchers at Semmelweis University analyzed how depression, smoking, obesity, sleep disorders, and other health problems are linked to difficult-to-treat rheumatoid arthritis (D2T-RA) and how this can inform treat-to-target (T2T) and individualized therapy.

Read Article
APR Safety Video Cover

Safety of Biologics and Novel Agents

Jack Cush, MD

Dr. Jack Cush reviews safety of biologics and novel agents.

Read Article
healthcare workers

WSJ: Nurse Practitioner Is Now the Hottest Job in Healthcare

Jack Cush, MD

The Wall St. Journal has published a perspective on nurse practitioners (NP) and their very promising careers.

Read Article
Sjogren's on chalkboard

RepurpSS-II: Hydroxychloroquine plus Leflunomide in Sjögren's

Jack Cush, MD

A small, pilot, phase 2b trial has shown that the combination of leflunomide and hydroxychloroquine (LEF+HCQ) was effective and safe in treating patients with active Sjögren's disease.

Read Article
lupus.nephritis.immunofluorescence.jpg

Trends and Innovations in Lupus Nephritis Clinical Trials

Jack Cush, MD

Xu et al. from Shanghai University have written an analysis of global lupus nephritis (LN) clinical trials and call for innovation.

Read Article
RheumNow Podcast square

Quiz Talk (5.22.2026)

Jack Cush, MD

Dr. Jack Cush talks of birthdays, Quizzes and journal articles this week on the podcast.

Read Article
H2H.BKZ.RZB

BE BOLD Week 16 data - Bimekizumab vs. Risankizumab in PsA

Jack Cush, MD

UCB has released the Week 16 results from BE BOLD trial that will be presented at EULAR 2026 in London on Saturday, June 6.

Read Article
WSJ: Nurse Practitioner Is Now the Hottest Job in Healthcare The Wall St. Journal has published a perspective on nurse practitioners (NP) and their very promising careers. https://t.co/YUasxB43ZO https://t.co/tkvKh0JEui

Links:

Dr. John Cush RheumNow ( View Tweet)
Cross-sectional study of 339 IBD pts (64% women, median 42yrs (32–53) found osteopenia by BMD in 34%, OP in 12%. Predictors not identified by multivariable analysis. Rheum eval led to OP Rx in 7% & vitamin D in 45% https://t.co/CNs7hb9KX8 https://t.co/aoesaW1pKw

Links:

Dr. John Cush RheumNow ( View Tweet)
30 yr Retrospective study of 1216 SLE hospitalizations in Barcelona - SLE flares & infections were most frequent. Hosp for infections signif. increased & in last 5yrs, exceeded Dz flares (34% vs. 26%). Younger pts had more flare hosp; older more infx hosp. Over time infx have https://t.co/TkUiXaoL1R
Dr. John Cush RheumNow ( View Tweet)
Quiz Talk (5.22.2026) Dr. Jack Cush talks of birthdays, quizzes, and journal articles this week on the podcast. https://t.co/LwX0XxgPhn https://t.co/4uVTQo6NLG

Links:

Dr. John Cush RheumNow ( View Tweet)
"Courage is resistance to fear, mastery of fear, not absence of fear." - Mark Twain https://t.co/xyJqiV7biI
Dr. John Cush RheumNow ( View Tweet)
Plasmacytoid dendritic cells (pDCs) have been strongly implicated in the pathogenesis of lupus, as their primary product, type I interferon (IFN-I), drive systemic lupus erythematosus (SLE) and cutaneous lupus erythematosus (CLE). A recent comprehensive review synthesizes the https://t.co/VaE295a2Ep
Dr. John Cush RheumNow ( View Tweet)
A Practical Approach to Myositis-Specific Antibodies https://t.co/14qow6zhsD

Links:

Rheumatology update aabdogafar ( View Tweet)
Study of 305 newly Dx axSpA pts (age 38 yrs; 55% male, Dx delay 6yrs, 75% B27+). Clinical Dx, without Xray/imaging in 12%, 5% developed sacroiliitis during 8 yr F/U. r-axSpA mostly male w/ ^CRP https://t.co/zWJDRdBSWC https://t.co/nWFnEgp5Zf

Links:

Dr. John Cush RheumNow ( View Tweet)
“Success is not final, failure is not fatal: it is the courage to continue that counts.” – Winston Churchill

Dr. John Cush RheumNow ( View Tweet)

Update on Multicentric Reticulohistiocytosis Have you ever seen multicentric reticulohistiocytosis (MRH)? Don't worry, it's a rare non-Langerhans cell histiocytosis condition characterized by papulonodular skin lesions and symmetric erosive polyarthritis, and it has only been https://t.co/1VrT8HFmva
Dr. John Cush RheumNow ( View Tweet)
FDA has approved benralizumab (Fasenra) for the treatment of adult and pediatric patients w/ hypereosinophilic syndrome (HES); based on the NATRON Phase III trial https://t.co/7se6qLsQoP https://t.co/64wC94hTTq

Links:

Dr. John Cush RheumNow ( View Tweet)
Immune-Mediated Inflammatory Diseases Following Uveitis A Korean insurance claims data study showed children and adolescents diagnosed with uveitis have a 7-fold increased risk of developing an immune-mediated inflammatory disorder (IMID). https://t.co/NJI4369ygL https://t.co/6mHK8hYMeG

Links:

Dr. John Cush RheumNow ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×